All News

Article

Expanding the IL-17 Therapeutic Landscape

Adela Castro, MD Jun 13, 2025

IL-17 inhibitors are an effective therapeutic for a broad spectrum of inflammatory and autoimmune diseases and its blockade has revolutionized management of diseases such as psoriasis, psoriatic arthritis and SpA. Is there a need for more medications within the same therapeutic class?

Article

Social Determinants of Health in SLE

EurekAlert! Jun 13, 2025

Social determinants of health (SDH), such as socioeconomic status and educational background are factors that are increasingly recognised as critical contributors to health outcomes in chronic diseases.

Very pleased to present at #EULAR2025 work @ArthritisAust on consumer involvement into research. Consumer involvement in research delivers: - better, more relevant research - better dissemination of results - competitiveness in today’s funding landscape POS1016-PARE @RheumNow https://t.co/0fhpsnGhdT

https://x.com/drdavidliew/status/1933482629367804281/photo/1

Maybe the pathogenesis gives us a clue on how to target things? Possibly the treatments which take down synovitis might not always help with nodules Christopher Edwards #EULAR2025 @RheumNow https://t.co/T6QHCS8709

What is new in SpA? ‼️nomenclature change: 🚫AS≠ Ankylosing spondylitis ✅AS= Axial spondyloarthritis -Helena Marzo-Ortega at #EULAR2025 @RheumNow

Delay hurts. Dx delay in axial SpA costs UK £3.1 billion annually. Avg time to dx = 8.5 yrs Avg dx cost = £187k/person Fixing delay could save £167k/person. Early Dx isn’t just better care—it’s economic policy. #EULAR2025 @RheumNow #AxialSpA #RMD https://t.co/eYEQ2rp94m

https://x.com/JihaRheum/status/1933492091457331458/photo/1

#EULAR2025 Abstr#OP0324 Cohort study of #lupus nephritis in Greece showed Earlier GC Discontinuation (D/C) & flare protection post-D/C is associated with renal response, low disease activity & HCQ use at GC D/C. Membranous LN & recent diagnosis were assoc w early GC D/C @RheumNow https://t.co/agFgyG5eaS

https://x.com/Yuz6Yusof/status/1933498445408391219/photo/1

About #Multidisciplinarity ... Dr Ihsane Hmamouchi talking about Multidisciplinary Approach to Migrant #Rheumatology Care #quotes #EULAR2025 #Invitedspeaker #outofthebox @RheumNow @epirheum https://t.co/RG6xpHejv9

https://x.com/Nellziade/status/1933503623708704963/photo/1

RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its Faculty

Diagnostic delay in #SpA 🔹️Data from the @Official_ASAS Study 🔹️4339 patients 🔹️Delay was 6.6 years 🔹️Longer in axSpA and IBD-SpA, shorter in PsA and pSpA 🔹️Associated with type of initial symptoms (shorter in peripheral) POS0909 #EULAR2025 @rheumnow https://t.co/3BMYFxbKiq

https://x.com/Nellziade/status/1933284700258283807/photo/1

#ANCA #vasculitis is not created equally REVEAL cohort 588 ANCA Initial & 12 months #BVAS (activity index) mean ⬇️BVAS over 1 yr in all groups #GPA #MPA #eGPA 5yr survival not = over time ⬆️survival in eGPA & GPA vs MPA #POS0329 #EULAR2025 @RheumNow @eular_org https://t.co/cUKytqNZnS

Is RA just one disease? No, & increasingly more efforts to subgroup RA on diff levels Simple approach - derived phenotypes map (independent of ACPA): - to broad histopath - to MTX response Omics is good, but still need to do the simple stuff better! #EULAR2025 OP0328 @RheumNow https://t.co/a8Vl7Kcjso

https://x.com/drdavidliew/status/1933460967989628949/photo/1

RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its faculty.

Live Daily Eular 2025 Recap Day 1 https://t.co/dLV83VcGuC

Dr. John Cush

Worth mentioning: the type of monoclonal protein is important for diagnosis. Different diseases with different therapies #EULAR2025 @RheumNow l https://t.co/5bbQnHV6CI

https://x.com/drdavidliew/status/1932790928185700426/photo/1

#vagal & #splenic #nerves most studied In #immune #system interaction #PNS can detect #inflammation use in #D2T #RA w active disease ? Key factors in #neurostimulation - many #EULAR2025 @RheumNow @eular_org #D2T in #RA session https://t.co/tCgpGtI5z2

The great debate: are cannabis and cannabinoids a valid treatment option in patients with rheumatic diseases? A thread 🧵👇🏼 @RheumNow #EULAR2025 https://t.co/KLZN9MvcFy

https://x.com/AurelieRheumo/status/1933167023678464465/photo/1

Interesting debate today #EULAR2025 about medical cannabis - where relative harms have come up. Would you rather be addicted to prescription opioids or recreational cannabis? (not going to argue about cannabis addiction - let’s say social impact is equal) @RheumNow

#RCT of #vagus #nerve #stimulation in #bDMARD-IR #RA Pts RESSET RCT +RA #RCT w #VNS But low response with stat significance ACR20 1/4 sham vs 1/3 VNS Would add on to new SoC? 🤔 #EULAR2025 @RheumNow #eular_org #D2T- RA-session https://t.co/tR1pLPBr74

So we used to get taught about bimodal age distribution of RA onset - young people and old people. Actually, it’s early middle age where RA diagnoses have now grown globally over 30y - right in peak productivity Global Burden of Disease data #EULAR2025 OP0240-HPR @RheumNow https://t.co/8yyrex00yy

https://x.com/drdavidliew/status/1933176266838217116/photo/1

Topics

All News

Expanding the IL-17 Therapeutic Landscape

Social Determinants of Health in SLE

Do you get our email newsletter?